AzTrials
AzTrials

Tobacco SmokingNCT06191419

Human Perception of Odors and Odor Blockers

A study testing Odorants in people with Tobacco Smoking and Smoking Behaviors, run by Tim McClintock at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to determine whether blockers of perception of key odorants in cigarette smoke have any utility in smoking cessation. The main question it aims to answer is: Can odor blockers be used to suppress perception of the intensity of cigarette smoke in ways that reduce the ability of the… Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Tobacco Smoking, Smoking Behaviors
What is being tested?
Odorants
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
1 siteUnited States
Study dates
5 Apr 2024to 15 May 2025
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Smoker

Who cannot join

  • Non Smoker
  • Self reported inability to smell or taste

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Kentucky

    Lexington, Kentucky, 40536

Other trials in United States

About this study

The goal of this clinical trial is to determine whether blockers of perception of key odorants in cigarette smoke have any utility in smoking cessation. The main question it aims to answer is:

  • Can odor blockers be used to suppress perception of the intensity of cigarette smoke in ways that reduce the ability of the odor of cigarette smoke to increase the urge to smoke.

Participants will be asked to smell up to 20 odor samples per session and report on odor pleasantness and desire to smoke.

Read the detailed description

The experimental treatments include controls (clean air, irrelevant odor), blocking odors, cigarette smoke odor, and cigarette smoke odor mixed with blocking odors or irrelevant odor. To obtain cigarette smoke odor a 1 inch length of a 1R6F research cigarette is burned to completion in a sealed 5 gallon chamber fitted with septa. Using a syringe fit with a needle and filter, 60 mL aliquots of smoke odor are obtained. These smoke odor aliquots, along with blocking odors, are injected into odor sample bags fit with a septum and a valve that can be attached to the CPAP nose mask worn by each participating smoker. Participants open the valve, inhale once through the nose, close the valve, and then remove the bag from the mask before reporting odor pleasantness and the desire to smoke. A 4 min wait period is enforced between each odor presentation to prevent odor adaptation and to allow acute motivational effects to subside. During these intervals, a nature documentary was available for viewing. Two measures of the desire to smoke are made. An objective method uses a validated relative reinforcing measure, requiring participants to record how many cigarettes they would purchase at each step along a logarithmically increasing price scale that ranges from $0 to $1,120 per cigarette. The breakpoint on this scale at which a participant is no longer willing to pay is the measure of the urge to smoke. As a subjective measure, participants report their urge to smoke as a value between 0 and 100. Participants also provide a forced choice measure of odor pleasantness, indicating either pleasant or unpleasant for each odor.

In a testing session a participant sniffs a mixture of blocking odors mixed with cigarette smoke, along with control odor samples. Presentation order is randomized. Each participant is assigned their own CPAP nose mask, and masks are disinfected after use. Participants also provide demographic (age, sex, ethnic and racial background) and smoking history information (cigarettes per day, preferred brand, age at onset, and time since last cigarette).

Being tested
Odorants
Keywords
Odors, Sensory perception, Nicotine addiction, Motivation
Medical subject headings
Tobacco Smoking, Smoking, Tobacco Use Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OdorantsOther

    Each smoker is assigned a CPAP nose mask. Odor sample bags are attached to the mask. Smokers open the valve, inhale once through the nose, close the valve, remove the bag from the mask and report on the odor.

Study groups in NCT06191419
Study groupRoleWhat they receive
Participants that SmokeExperimentalEach smoker is asked to smell up to 20 samples per session. Samples include controls (clean air, irrelevant odor), blocking odors, cigarette smoke, and cigarette smoke mixed with blocking odors or irrelevant odors.
Receives: Other: Odorants

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cigarette Purchase Task

    The Cigarette Purchase Task (Strickland et al., 2016) requires selecting how much the smoker is willing to spend for a single cigarette (their preferred brand) from a list of 19 amounts ranging from $0.00 (free) to $1,120. The measure from the selections is the breakpoint where the participants are no longer willing to purchase. These data are skewed and are log transformed (after adding 0.01) for statistical analysis.

    Measured: 3 hours (total for all outcome measures)

  2. Desire to Smoke

    A rating of participant's desire to smoke on a scale of 0 - 100, where a higher score indicates increased desire.

    Measured: 3 hours (total for all outcome measures)

Secondary outcomes (1)
  1. Odor Pleasantness Score

    Participants complete a forced-choice test by rating whether the odor is pleasant or unpleasant. Responses were recorded as a binary measure where 0=unpleasant and 1=pleasant. Scores range from 0 to 1, with higher score indicate greater odor pleasantness.

    Measured: 3 hours (total for all outcome measures)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2024
  2. Study start5 Apr 2024
  3. Primary completion15 May 2025
  4. Study completion15 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Model description
Each subject experiences and reports on all of the odor blocker and control treatments.
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06191419
Sponsor's protocol ID
43123
Other IDs
1K18DC020155
Status last verified
Jun 2026
First submitted
20 Dec 2023
Last updated
23 Jul 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Odorants in people with Tobacco Smoking and Smoking Behaviors, run by Tim McClintock at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cigarette Purchase Task (time frame: 3 hours (total for all outcome measures)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in